Long noncoding RNA FTX is associated with prognosis of glioma patients

Abstract

Background: Long noncoding RNAs play influential roles in the progression of many types of human malignancies. The present study aimed to explore the prognostic value of long noncoding RNA FTX (FTX) on patients with glioma. Methods: FTX expression in glioma specimens and matched adjacent non-neoplasm specimens was examined by a quantitative real-time polymerase chain reaction assay. Furthermore, assays of the relationships between FTX expression and clinicopathologic characteristics of patients with glioma were also performed. Kaplan-Meier methods were applied for the assays of the overall survival (OS) and progression-free survival (PFS) of patients and Cox regression assays were used to analyze the clinical value of FTX used as a possible biomarker. Results: FTX levels were significantly up-regulated in glioma specimens compared to the paired non-neoplasm specimens (p < 0.01). Furthermore, high FTX expression in neoplasm tissues was dramatically associated with World Health Organization grade (p = 0.001) and Karnofsky Performance Score (p = 0.009). Kaplan-Meier assays with 187 patients revealed that patients with high level of FTX expression displayed poorer OS (p = 0.002) and PFS (p = 0.000). Subsequently, multivariable Cox regression analysis identified FTX expression as an independent prognostic factor of unfavorable survivals in glioma (OS: p = 0.001; PFS: p = 0.002). Conclusions: These findings indicated that FTX may be a novel predictor for prognostic assessment of glioma patients. However, studies conducted with larger numbers of patients are essential to confirm our findings.

Long non-coding RNA FTX predicts a poor prognosis of human cancers: a meta-analysis

“…As shown by the search flow diagram ( Figure 1 ), a total of 11 studies [ 9–13 , 15 , 19–23 ] with 1210 patients were enrolled in this meta-analysis satisfied the inclusion criteria, including 3 studies on CRC, 3 studies on HCC, 2 studies on GC, and 1 study each on RCC, OSC, and glioma. The included studies were published from 2015 to 2020, and sample sizes ranged from 30 to 187 patients.…”

Long non-coding RNA FTX predicts a poor prognosis of human cancers: a meta-analysis

“…As shown by the search ow diagram (Fig 1),a total11 studies [7][8][9][10][11][12][15][16][17][18][19] with 1210 patients were enrolled in this meta-analysis according to the inclusion criteria, including 3studies on CRC, 3studies on HCC, 2 studies on GC, 1 study on RCC, 1 study on OSC, and 1 study on glioma. The included studies were published from 2015 to 2020, and sample sizes ranged from 30 to 187 patients.…”

“…2d) in 9 studies [7][8][9][10][11][12][17][18][19] (2 studies on CRC 2 studies on GC 3 studies on HCC, 1 study on RCC, and 1 study on OSC),and later TNM/clinical stage (III + IV vs I + II : OR = 2.38, 95% CI = [1.85, 3.06], p < 0.001, Fig. 2f) in 10 studies [7][8][9][10][11][15][16][17][18][19] (3 studies on CRC 2 studies on GC 2 studies on HCC, 1 study on RCC, 1 study on OSC, and 1 study on glioma).The overexpression of FTX was not associated with gender (male vs female: OR = 0.87, 95% CI = [0.68, 1.12], p = 0.271, Fig. 2a) in all aforementioned 11 studies and differentiation (low vs high and moderate: OR = 1.33, 95% CI = [0.53, 3.33], p = 0.546, Fig.…”

“…A meta-analysis was conducted using the data from survival analysis by Kaplan-Meier method in 8 studies [8,9,11,12,15,16,18,19] (3 studies on HCC,2 studies on CRC,1study on GC,1 study on OSC, and 1study on glioma). The pooled HRs for OS was extracted from these 8 heterogeneous studies(I 2 = 68.3%, p = 0.002) with 937 patients, and the result showed a signi cant correlation between high FTX expression and a shorter OS(high vs low: HR = 1.58, 95% CI = [1.13, 2.20], p 0.007, Fig.…”

“…Another meta-analysis was conducted using the data from survival analysis by multivariate Cox regression model in four studies [8,12,15,16] (1 study on CRC, 1 study on HCC, 1 study on OSC,1 study on glioma), which included531 patients. The role of FTX as an independent predictive factor for OS of patients with cancer was assessed.…”